Lisinopril ( DrugBank: Lisinopril )


7 diseases
告示番号疾患名(ページ内リンク)臨床試験数
19ライソゾーム病1
46悪性関節リウマチ1
49全身性エリテマトーデス1
66IgA腎症2
67多発性嚢胞腎3
113筋ジストロフィー2
222一次性ネフローゼ症候群1

19. ライソゾーム病


臨床試験数 : 899 薬物数 : 684 - (DrugBank : 99) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 182
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2007-007482-21-GB
(EUCTR)
09/11/200917/08/2009Multi-center, Open-label Study of the Safety and Efficacy of Control of Proteinuria with ACE Inhibitors and ARBS in Patients with Fabry Diseaswe Who Are receiving Farazyme : Tha Farazyme + Arbs + ACE inhibitors Treatments (FAACET) Study: The FAACET Study - The FAACET StudyMulti-center, Open-label Study of the Safety and Efficacy of Control of Proteinuria with ACE Inhibitors and ARBS in Patients with Fabry Diseaswe Who Are receiving Farazyme : Tha Farazyme + Arbs + ACE inhibitors Treatments (FAACET) Study: The FAACET Study - The FAACET Study Fabry disease with proteinuria.
MedDRA version: 9.1;Level: LLT;Classification code 10018058;Term: Gene genetic abnormality
MedDRA version: 9.1;Classification code 10037032;Term: Proteinuria
Trade Name: perdix
Product Name: perdix
Trade Name: Zestoretic 10,20
Product Name: ZESTORIC
Trade Name: INNOZIDE
Product Name: innozide
Trade Name: lisinopril
Product Name: lisinopril
Trade Name: zestril
Product Name: zestril
Trade Name: coversyl
Product Name: coversyl
Trade Name: coversyl PLUS
Product Name: coversyl PLUS
Trade Name: Accupro
Product Name: Accupro
Trade Name: Accuretic
Product Name: Accuretic
Trade Name: lopace
Product Name: lopace
Trade Name: lopace
Product Name: lopace
Trade Name: triapin
Product Name: triapin& triapin Mite
Salford Royal NHS Foundation TrustNULLNot Recruiting Female: yes
Male: yes
Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yesUnited Kingdom

46. 悪性関節リウマチ


臨床試験数 : 4,356 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2005-005295-32-GB
(EUCTR)
01/02/200602/12/2005Trial in rheumatoid arthritis of lisinopril (TRALIS) - TRALISTrial in rheumatoid arthritis of lisinopril (TRALIS) - TRALIS Rheumatoid arthritisTrade Name: Lisinopril
Product Name: Lisinopril
Product Code: N/A
Research and Development Department, Addenbrookes NHS Foundation TrustNULLNot Recruiting Female: yes
Male: yes
200 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yesUnited Kingdom

49. 全身性エリテマトーデス


臨床試験数 : 993 薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04486118
(ClinicalTrials.gov)
October 1, 202128/10/2019Centrally Acting ACE Inhibition in SLEA Novel Phase 2 Double-blind, Randomized, Controlled Clinical Trial to Evaluate the Efficacy of Centrally Acting, Non-toxic ACE Inhibition in Cognitive Impairment Associated With SLESystemic Lupus ErythematosusDrug: Lisinopril Pills;Drug: Benazepril PillNorthwell HealthLupus Research AllianceRecruiting18 Years55 YearsAll36Phase 2United States

66. IgA腎症


臨床試験数 : 275 薬物数 : 258 - (DrugBank : 82) / 標的遺伝子数 : 36 - 標的パスウェイ数 : 140
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-C000000006
2005/01/0101/08/2005Lisinopril only and a combination of lisinopril and losartan for IgA nephropathy with focal mesangial proliferation in children: A randomized controlled trial of efficacy and safetyLisinopril only and a combination of lisinopril and losartan for IgA nephropathy with focal mesangial proliferation in children: A randomized controlled trial of efficacy and safety - Lisinopril only and a combination of lisinopril and losartan: A randomized controlled trial(JSKDC01) IgA nephropathy in childrenLisinopril for 2 years
Lisinopril+losartan for 2 years
Japanese Study group of Kidney Disease in ChildrenNULLComplete: follow-up complete2years-old18years-oldMale and Female110Not selectedJapan
2JPRN-C000000373
1998/08/0101/04/2006Lisinopril for IgA nephropathy with focal mesangial proliferation in childrenLisinopril for IgA nephropathy with focal mesangial proliferation in children - Lisinopril for IgA nephropathy with focal mesangial proliferation in children IgA nephropathy in childrenLisinopril for 2 yearsThe Japanese Pediatric IgA Nephropathy of Treatment Study GroupNULLComplete: follow-up complete2years-old18years-oldMale and Female50Not selectedJapan

67. 多発性嚢胞腎


臨床試験数 : 221 薬物数 : 212 - (DrugBank : 55) / 標的遺伝子数 : 40 - 標的パスウェイ数 : 151
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01885559
(ClinicalTrials.gov)
January 200617/6/2013HALT Progression of Polycystic Kidney Disease Study BHALT Progression of Polycystic Kidney Disease Study BKidney, PolycysticDrug: Lisinopril;Drug: Telmisartan;Drug: PlaceboNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Boehringer Ingelheim;Merck Sharp & Dohme Corp.;Polycystic Kidney Disease Foundation;University of Pittsburgh;Washington University School of MedicineCompleted15 Years64 YearsAll486Phase 3United States
2NCT00283686
(ClinicalTrials.gov)
January 200626/1/2006HALT Progression of Polycystic Kidney Disease Study AHALT Progression of Polycystic Kidney Disease Study AKidney, PolycysticDrug: Lisinopril;Drug: Telmisartan;Drug: Placebo;Other: Standard Blood Pressure Control;Other: Low Blood Pressure ControlNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Boehringer Ingelheim;Merck Sharp & Dohme Corp.;Polycystic Kidney Disease Foundation;University of Pittsburgh;Washington University School of MedicineCompleted15 Years64 YearsAll558Phase 3United States
3EUCTR2005-003182-16-GB
(EUCTR)
26/08/200529/07/2005Blood Pressure Optimisation In Patients With Polycystic Kidney Disease And Hypertension By Rotation Through The Main Therapeutic Classes Of Antihypertensive Drugs.Blood Pressure Optimisation In Patients With Polycystic Kidney Disease And Hypertension By Rotation Through The Main Therapeutic Classes Of Antihypertensive Drugs. Polycystic kidney diseaseTrade Name: CARDURA
Product Name: DOXAZOSIN
Trade Name: MONOCOR
Product Name: BISOPROLOL
Trade Name: ZESTRIL
Product Name: LISINOPRIL
Trade Name: ISTIN
Product Name: AMLODIPINE
Trade Name: AMIAS
Product Name: CANDESARTAN
Trade Name: APRINOX
Product Name: BENDROFLUMETHIAZIDE
Addenbrooke's Hospital TrustNULLNot Recruiting Female: yes
Male: yes
42 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yesUnited Kingdom

113. 筋ジストロフィー


臨床試験数 : 646 薬物数 : 471 - (DrugBank : 105) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 170
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01126697
(ClinicalTrials.gov)
February 201018/5/2010Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular DystrophiesPITT0908: Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular DystrophiesDuchenne Muscular Dystrophy;Becker Muscular Dystrophy;Limb Girdle Muscular DystrophyDrug: Coenzyme Q10 and LisinoprilCooperative International Neuromuscular Research GroupUnited States Department of DefenseCompleted8 YearsN/AAll63Phase 2/Phase 3United States;Canada;Japan
2NCT01982695
(ClinicalTrials.gov)
March 200929/10/2013Cardiomyopathy in DMD: Lisinopril vs. LosartanCompare Efficacy of the Angiotensin Converting Enzyme Inhibitor (ACEi) Lisinopril With Angiotensin II Receptor Antagonist Losartan (ARB) for the Cardiomyopathy of Duchenne Muscular DystrophyDuchenne Muscular Dystrophy (DMD);CardiomyopathyDrug: Losartan;Drug: LisinoprilNationwide Children's HospitalBoston Children’s Hospital;University of California, Davis;Unverisity of Kansas Medical Center;University of Minnesota - Clinical and Translational Science Institute;St. Louis Children's HospitalCompletedN/AN/AMale23N/AUnited States

222. 一次性ネフローゼ症候群


臨床試験数 : 310 薬物数 : 295 - (DrugBank : 117) / 標的遺伝子数 : 63 - 標的パスウェイ数 : 194
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00814255
(ClinicalTrials.gov)
December 200822/12/2008Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical TrialNovel Therapies for Resistant Focal Segmental GlomerulosclerosisFocal Segmental GlomerulosclerosisDrug: Adalimumab;Drug: Lisinopril, losartan, and atorvastatin;Drug: galactoseNew York University School of MedicineUniversity of Michigan;The Cleveland Clinic;National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed1 Year65 YearsAll32Phase 2United States;Canada